Effect of Medotilin on the functional state of the brain in patients who have suffered acute cerebrovascular accidents of ischemic type

Authors: V.Y. Teshchuk, N.V. Teshchuk

Military Clinical Medical Center of the South Region of Ukraine, Odesa, Ukraine


Abstract

This article analyzes the impact of Medotilin (at a dose of 4.0 ml — 1,000 mg intramuscularly once daily for 30 days) on cerebral hemodynamics and bioelectric activity of the brain in patients with acute cerebrovascular accident (ACVA) by ischemic type.

It was found that Medotilin in this group of patients improves cerebral hemodynamics and causes reorganization in the bioelectric activity of the brain. Type of reorganization is determined by hemispheric localization of ACVA. Positive impact of Medotilin on cerebral hemodynamics and bioelectric activity of the brain in patients, who have suffered ischemic ACVA, gives reason to recommend the wider use of Medotilin in the system of rehabilitation in this group of patients.

Keywords: acute cerebrovascular accident; ischemic stroke; Medotilin; rehabilitation; cerebral hemodynamics; bioelectric activity of the brain.

Published in the journal “International Neurological Journal” № 3 (89)’2017

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design